Holloway Michael Andrew 4

What Happened
Michael Andrew Holloway, a director of Lixte Biotechnology Holdings, received an award of 15,000 restricted share units (RSUs) that vested on July 1, 2026. The reported transaction is coded as an award/acquisition (A) at $0.00 per RSU (no cash paid). According to the filing, these RSUs vested upon satisfaction of the applicable performance conditions and represent contingent rights to receive one share of common stock per RSU.

Key Details

• Transaction date: July 1, 2026; Form 4 filed July 2, 2026 (timely filing).
• Transaction type/code: Award/Grant (A); 15,000 RSUs acquired at $0.00.
• Holdings after transaction: Footnote states Column 5 includes the 15,000 newly awarded RSUs plus 25,000 RSUs (all vested) — totaling 40,000 RSUs reported as vested.
• Footnotes: F1 explains each RSU converts to one share upon vesting and the performance conditions have been satisfied. F2 clarifies the Column 5 total includes both the new 15,000 and 25,000 previously awarded RSUs.
• No mention of tax withholding, cashless sale, or a 10b5-1 plan in the filing.

Context
RSUs are a form of equity compensation that convert into shares when vesting conditions are met; this filing reports vesting (an acquisition of vested RSUs), not a market purchase or sale. Such awards are routine for compensation and do not, by themselves, indicate a director buying or selling stock in the open market.